Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Physiology of Itch
Description
The discussion on the 'Physiology of Itch' explores the neurological mechanisms behind itch sensation and scratching behavior. The speaker elaborates on the process of itch transmission, which begins when histamine is injected into the skin, triggering action potentials that travel through peripheral nerves to the spinal cord and then to the brain. Unlike pain, which typically causes a withdrawal response, itch prompts individuals to scratch the affected area, often exacerbating skin lesions. The speaker notes that many chronic itch conditions are not driven by histamine but rather by various other factors such as cytokines. Atopic dermatitis is discussed as a model for understanding inflammatory itch, highlighting how specific immune responses and cytokines damage the skin barrier and communicate with the sensory nervous system. Recent findings indicate that itch pathways can be effectively targeted therapeutically, with several promising interventions emerging, including JAK inhibitors. The potential of therapies that target endogenous opioid pathways, like the Kappa opioid receptor, is introduced, suggesting this could offer a new angle for treatment. The talk concludes with a positive outlook on the advancements in itch therapeutics and ongoing clinical trials, emphasizing the importance of continued research in unraveling the complexities of itch physiology.
View moreConclusions
- Itch is a complex sensation that involves multiple pathways and can be triggered by factors beyond histamine, including cytokines and neuropeptides.
- Chronic itch conditions vary widely in their underlying mechanisms, suggesting that different therapeutic approaches may be necessary depending on the specific type of itch.
- Dupilumab has shown efficacy in treating various chronic itch conditions, highlighting the potential for targeted therapies that modulate specific pathways in itch physiology.
- Type 2 cytokine signaling is a key mediator in atopic dermatitis and other itch disorders, indicating that inhibition of these pathways can effectively alleviate itch.
- New therapeutic compounds, such as JAK inhibitors and kappa opioid receptor agonists, are emerging as promising treatments for neuropathic and chronic itch, including conditions such as notalgia paresthetica.
- There is considerable potential to leverage insights from basic science to develop innovative therapies for chronic itch, marking a significant advancement in the field of dermatology.
- Mu et al. Science 2017
- Mishra et al. Cell 2013
- Sun and Chen Nature 2007
- Liu et al. Cell 2009
- Han et al. Nat Neuro 2013
- Andrews' Disease of the Skin Atlas 2018
- Kim et al. Sci Transl Med 2013
- Kim et al. J Immunol 2014
- Oetjen et al. Cell 2017
- Wang et al. Immunity 2020
- Usoskin et al. Nat Neurosci 2015
- Yosipovitch et al. Nat Med 2023
- Auyeung et al. Ann Allergy Asthma Immunol 2023
- Jeon et al. J Dermatol Treat 2021
- Wang et al. JAMA Dermatol 2019
- Kim et al. NEJM 2023
- Nguyen et al. eLife 2021